BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31900258)

  • 21. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
    Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
    Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
    Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
    Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
    [No Abstract]   [Full Text] [Related]  

  • 24. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
    Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
    Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase.
    Sooraj D; Sun C; Doan A; Garama DJ; Dannappel MV; Zhu D; Chua HK; Mahara S; Wan Hassan WA; Tay YK; Guanizo A; Croagh D; Prodanovic Z; Gough DJ; Wan C; Firestein R
    Mol Cell; 2022 Jan; 82(1):123-139.e7. PubMed ID: 34910943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.
    Delehouzé C; Godl K; Loaëc N; Bruyère C; Desban N; Oumata N; Galons H; Roumeliotis TI; Giannopoulou EG; Grenet J; Twitchell D; Lahti J; Mouchet N; Galibert MD; Garbis SD; Meijer L
    Oncogene; 2014 Dec; 33(50):5675-87. PubMed ID: 24317512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
    Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F
    Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
    Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ
    Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRD4 facilitates replication stress-induced DNA damage response.
    Zhang J; Dulak AM; Hattersley MM; Willis BS; Nikkilä J; Wang A; Lau A; Reimer C; Zinda M; Fawell SE; Mills GB; Chen H
    Oncogene; 2018 Jul; 37(28):3763-3777. PubMed ID: 29636547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
    Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
    Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
    Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
    J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.